Phaseline

Targets › BCL2L1

BCL2L1 (Bcl-2-like protein 1): drug programs, companies and trials

6 programs from 5 companies in 14 trials: 12 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.

Potent inhibitor of cell death. Inhibits activation of caspases. (UniProt, Q07817)

Open in Phaseline: the race on BCL2L1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AbbVieNavitoclax
Apoptosis regulator Bcl-2 inhibitor; Apoptosis regulator Bcl-X inhibitor; Apoptosis regulator Bcl-W inhibitor
BCL2, BCL2L1, BCL2L2, BCL2L2-PABPN1Phase 3Myelofibrosis (MF); Myeloproliferative Neoplasm; Mantle Cell Lymphoma Refractory; High Grade Serous Carcinoma …Dec 2026
National Cancer Institute (NCI)Pelcitoclax
Bcl-2/Bcl-XL inhibitor
BCL2, BCL2L1Phase 1Advanced Endometrial CarcinomaFeb 2027
Elizabeth Stover, MD, PhDDT2216
BCL-XL proteolysis-targeting chimera (PROTAC) degrader
BCL2L1Phase 1Ovarian CancerJun 2027
Chia Tai Tianqing Pharmaceutical GroupTQB3142 for injection
BCL-XL inhibitor
BCL2L1Phase 1Advanced Malignant TumorsDec 2027
AbbVieSurzetoclax
BCL2 family protein inhibitor
BCL2L1Phase 1Multiple MyelomaDec 2030
Ascentage Pharma GroupAPG-1252
BCL-2 family protein inhibitor
BCL2, BCL2L1, BCL2L2, MCL1Phase 1EGFR Positive Non-small Cell Lung Cancer–

Conditions

Multiple Myeloma (1) Advanced Malignant Tumors (1) Advanced Endometrial Carcinoma (1) Ovarian Cancer (1) Myelofibrosis (MF) (1) Myeloproliferative Neoplasm (1) Mantle Cell Lymphoma Refractory (1) High Grade Serous Carcinoma (1) Myeloid Malignancy (1) Refractory Acute Lymphoblastic Leukemia (1) Recurrent Acute Myeloid Leukemia (1) Metastatic Malignant Solid Neoplasm (1)

Modalities

small molecule (5), mixed (1)

Companies

AbbVie (2) Chia Tai Tianqing Pharmaceutical Group (1) National Cancer Institute (NCI) (1) Elizabeth Stover, MD, PhD (1) Ascentage Pharma Group (1)

Related targets

BCL2 (3) BCL2L2 (2) BCL2L2-PABPN1 (1) MCL1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.